We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Top Five IVD Sector Trends of 2015 Announced

By LabMedica International staff writers
Posted on 21 Dec 2015
Print article
Among the in vitro diagnostic (IVD) testing trends in 2015 were smaller molecular instruments, better information technology (IT) systems, and progress on use of sequencing in clinical medicine. These and additional findings were based on research covered in three new healthcare market reports.

Three main segments drive IVD sector. Kalorama Information (New York, NY, USA) describes 5 main trends based on their recently published 3 reports (see Related Links below), which delve into some of the fastest-growing and most critical areas of clinical diagnostics: cancer, infectious diseases, and molecular assays and systems. Together, these areas represent approximately 40% of the overall IVD market. The rate of growth for the combined segments is outpacing the growth of the overall IVD market by roughly 2 extra percentage points each year (+2% CAGR). Several subsegments of the cancer and molecular diagnostics markets are also growing at rates of over 8% each year.

Molecular Point-of-Care (POC) Becomes Reality: Alere announced its Alere i Influenza A & B that provides molecular flu results in less than 15 minutes. Cepheid launched its highly portable 9 inches tall GeneXpert Omni, enabling unprecedented access to accurate, fast diagnosis for patients suspected of having TB, HIV, and Ebola. Such products push infectious disease testing into the POC and near-patient testing arena, allowing providers to initiate treatment during the same visit or day.

Energetic Competitive Activity: The leader in IVD in 2015 remains the same as in 2014, but there was plenty of market activity, with scores of acquisitions, partnership deals, and distribution agreements. Roche Diagnostics remains the largest supplier of clinical diagnostics products; its product sales are still almost twice its nearest competitor. Roche stayed active in 2015, including a deal with Sigma-Aldrich, acquiring GeneWeave BioSciences, and becoming majority shareholder in cancer genomics company Foundation Medicine.

One competitor, automated nucleic acid extraction pioneer Qiagen, continued to grow, with close to 30% increase in IVD sales since 2010. Now Qiagen’s clinical business is moving from a base in infectious diseases to cancer testing and personalized medicine. It markets over 500 products in four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).

Liquid Biopsy: Numerous liquid biopsy tests and enterprises progressed in 2015. Genomic DNA amplified or sequenced from circulating tumor cells (CTCs), circulating tumor cell DNA (ctDNA), and circulating cell-free DNA (cfDNA) harbor complementary information on mutations relevant for the treatment of individual cancer patients. The technology has had its ups and downs but is still in contention. These applications will likely impact and determine the future standard of oncology care. cfDNA can be applied more broadly and will likely determine standard of care in oncology, transplant medicine, and cardiovascular disease. This emerging field has already made a huge impact on prenatal care. CTC technology is much more mature than that of cfDNA. Veridex (Janssen Diagnostics) has pioneered CTC testing.

Information Technology and Genomics: 2015 saw progress in use of IT for genomic medicine. Hundreds of genome studies are underway, involving sometimes hundreds of thousands of patient test results. Data-sharing, through private and public consortia, has become essential. The Global Alliance is a diverse international coalition of over 140 member organizations working together on open interfaces and catalytic projects to enable effective and responsible data-sharing and guide this quickly evolving field.

Related Links:
The World Market for Molecular Diagnostics, 6th Edition, report
The World Market for Cancer Diagnostics, 6th Edition, report
The World Market for Infectious Disease Diagnostic Tests, report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.